In the Canadian CanCOLD cohort, 48 of 685 participants (7.0 %) without airflow obstruction were newly classified as having COPD under the minor-criteria path, while 105 of 656 participants (16.0 % ...

Verona Pharma plc has announced the upcoming presentation of ten posters at the American Thoracic Society Conference 2025, highlighting analyses from its Phase 3 ENHANCE studies of Ohtuvayre ...

--Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre for the ...

The ENHANCE posters highlight subgroup analyses of patients when used as monotherapy, in patients with COPD and comorbid cardiac disorders and, separately, in patients with COPD and comorbid type ...

Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This in-depth analysis shows that the Global Asthma and COPD Drugs Market, valued at ...

The current study provides a secondary analysis of two previously published trials investigating the impact of long-acting bronchodilators on night-time oxygen saturation in 106 patients with ...

Among those with asthma and concurrent COPD, the mean (SD) annual COPD exacerbation rate pre–mepolizumab initiation was 1.88 (1.96) overall and 2.80 (1.99) in the subgroup of patients with 1 or ...

In the first half of 2024, several U.S. health care professionals discussed the price of inhalers for patients with COPD on X, formerly Twitter, according to a tracker from Creation Healthcare.In ...

Presenter: Dave Singh, M.D., Professor, University of Manchester Location: A1 Late Breaking Poster Presentation Title: The safety and PK of an inhaled pan JAK inhibitor (KN-002) in subjects with COPD ...

Some of the risk factors for COPD are age, poor nutrition and pollution. Host factors • Age • Susceptibility (e.g. alpha-1 antitrypsin deficiency) or a family history of COPD • Poor lung growth and ...